Methods:We did an ambispective analysis to study the clinicopathological characteristics, treatment patterns and outcome of microinvasive breast cancer.Included patients from the period January 2017 to December 2023 in both retrospective and prospective manner.The demographic profile of patients, tumor characteristics(unifocal vs multifocal disease, ER/PR/HER 2 status), surgical details, lymph node status, details of adjuvant treatment received.Results: A total of 120 patients were included, with a median age of 50.5 years (range 22-86).50(41.7%) premenopausal and 70 (58.3%)postmenopausal.Surgical intervention included breast-conserving surgery in 28 (23.3%) and modified radical mastectomy in 88 patients (73.3%).59 (49.2%)MIBC with DCIS and 1 (0.8%) MIBC with LCIS.The majority had multifocal invasion (80/120,66.7%), and 88/120(73.3%)presented with grade 3 tumors.Comedo-type necrosis was observed in 107 patients (89.2%), and lymphovascular emboli were noted in only 6 patients (5%).Only 3 patients (2.5%) had micrometastasis in lymph nodes.HR and HER-2 status showed 66 patients (55%) were HER-2 positive, 23 (19.2%) were HR and HER-2 positive, 22 (18.3%) were only HR positive, and 7 (5.8%) were triple negative.Treatment patterns included adjuvant chemotherapy in 11 patients (9.2%), chemotherapy with trastuzumab in 40 patients (33.3%), and adjuvant hormone therapy in 12 patients (10%).Adjuvant Radiation received by 18/120 (15%).At a median follow-up of 52.8 months with 95% CI (44.5-61.2) and median OS was 141 months with 95% CI(139.0-143.77).Conclusions: MIBC associated with good prognosis; The high prevalence of highgrade tumors and HER-2 positivity shows the need for tailored treatment approaches.
Atmane et al. (Fri,) studied this question.